INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
INmune Bio has submitted regulatory filings to the European Medicines Agency seeking Orphan Drug Designation and scientific advice for Ebstrocel™, a pooled allogeneic umbilical cord-derived mesenchymal stromal cell therapy developed for recessive dystrophic epidermolysis bullosa (RDEB). These steps support the company’s planned EU Marketing Authori…